作者: Gunnar J Hanson
关键词: Biology 、 Interleukin 、 Pharmacology 、 Orally active 、 Rheumatoid arthritis 、 Cytokine 、 Drug 、 p38 mitogen-activated protein kinases 、 Enzyme 、 Patent literature
摘要: Inhibition of p38 kinase is evolving as an approach to the discovery new anti-inflammatory agents. Inhibitors this enzyme modulate cytokine production, especially pro-inflammatory TNF-α and IL-1. These cytokines others mediate a wide spectrum diseases, notably rheumatoid arthritis. Cytokine modulators are expected be disease modifying The lead molecules disclosed in patent literature fall into class termed 1-pyridinyl-2-phenylazoles; compounds encompasses promising drug candidates that non-peptide, orally active, low molecular weight selective for p38. Structural characteristics inhibitors background discussed.